Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its 2024 Healthy Future Report, sharing actions to advance its sustainability strategy.

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

[Operator Instructions] Please note, this call is being recorded and I will be standing by, should you need any assistance. It is now my pleasure to turn today's program ... on Form 10-K filed ...

During the first quarter of 2025, the SUMMIT Study advanced with the activation of additional sites and continued progress in patient ... response to Teva's Abbreviated New Drug Application ...

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

The clerical overhead of enrolment forms navigated ... efficient copay assistance programs to understand the patient journey in depth. Cost: technology should reduce program overhead.

specialty pharmacies are responsible for distributing therapies to the patient on behalf of the manufacturer, so they need a centralised application to support the entire process of patient intake ...

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to ...